All In Biotech

Drug Trial Radar · NCT06975150

Efficacy and Safety of HK-660S in the Treatment of Primary Sclerosing Cholangitis

A Randomized, Double-blind, Placebo-controlled, Parallel Group, 12 Weeks, Phase 2b Clinical Study to Evaluate the Efficacy and Safety of HK-660S in Patients With Primary Sclerosing Cholangitis (PSC)

Last checked: Nov 19, 2026Latest source record: May 16, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 105 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

105

Planned (sponsor's estimate)

Start

Aug 18, 2025

Primary completion

Aug 30, 2028

Study completion Aug 30, 2028

Sponsor

Lead sponsor
CuromeBiosciencesIndustry
Sponsor type
Industry
First posted
May 16, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The cause of PSC is unknown.To date, there is no treatment besides liver transplantation proven to improve PSC prognosis. However, there is a clear medical unmet need yet for patients with PSC, due to risks and complications of liver transplantation. This is a two-part, Phase 2b, randomized, double-blind, placebo-controlled study designed to assess the efficacy and safety of HK-660S in patients with PSC. The primary objective is to evaluate the effects of HK-660S on serum ALP improvement (reduction of 20% or more) over 12 weeks of treatment in patients with PSC.

Conditions

  • Primary Sclerosing Cholangitis (PSC)

Interventions

  • HK-660S 100mgDrug

    Administered orally

  • HK-660S 200mgDrug

    Administered orally

  • PlaceboDrug

    Administered orally

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of subjects who show improvement of ALPTime frame: 12 weeks from baseline

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.